Author(s)

Evrard Narcisse Séka¹, Bertrand Ghislain Compaoré¹, Bassané Alain Wilfried Mossé¹, Siham Jaba¹, Kouadio Davy N’chiépo¹, Maroua Benlemlih^1,2, Hasnae Bouhia¹, Mohammed Adnane Tazi³, Sanae El Majjaoui^1,4, Noureddine Benjaafar^1,4

¹Department of Radiotherapy, National Institute of Oncology, Rabat, Morocco.
²Department of Radiotherapy, Mohammed V Military Hospital, Rabat, Morocco.
³National School of Public Health, Rabat, Morocco.
⁴Mohammed V University in Rabat, Rabat, Morocco.

Introduction: External-beam radiation therapy boost is a treatment option in cervical cancer when brachytherapy is not feasible. Though less effective than brachytherapy, some encouraging results have been reported from some institutions experiences. We conducted this study to assess outcomes of EBRT boost for our patients at National Institute of Oncology in Rabat. Patients and Methods: We collected data from patients treated for cervical cancer between January 2012 and December 2015. Patients, tumor and treatment characteristics were collected. Overall survival (OS), disease-free survival (DFS) and prognostic factors influencing DFS were assessed. Results: One hundred and thirty-three patients were enrolled. Median age was 52 years. Patient haemoglobin level ranged from 3.9 to 15.5 g/dl [mean: 11.2 g/dl]. Most tumors were classified stage III/IVA (63.2%) according to the FIGO classification. Regional lymph node metastases (pelvic and or para-aortic) were observed in 45.1%. Median total dose to tumor was 69.6 Gy (ranging from 66 to 70 Gy). Overall treatment time was protracted, with a median of 60 days. Most of patients received concurrent chemotherapy (94.7%) and the number of cycle ranged from 2 to 7 (median = 5). The follow-up median was 31.3 months, ranging from 6.2 to 96.8 months. At the first visit, most patients achieved complete response (80.5%). Five years OS and DFS were 47% and 44% respectively. In univariate and multivariate analysis, regional lymph nodes metastasis (presence or absence) and haemoglobin level (≤11 g/dl and >11 g/dl) were the two significant and independent prognostic factors influencing DFS (HR: 1.86; p = 0.01 for the former) (HR: 0.59; p = 0.03 for the latter). Conclusion: Our study showed that EBRT boost in conventional fractionation was an acceptable treatment option for cervical cancer unamenable to brachytherapy, especially in the two subgroups of patients that are those without pelvic and/or para-aortic lymph node metastasis and those with haemoglobin level above 11 g/dl.

Cervical Cancer, External Beam Radiation Therapy Boost, Survival, Prognostic Factors

Séka, E. , Compaoré, B. , Mossé, B. , Jaba, S. , N’chiépo, K. , Benlemlih, M. , Bouhia, H. , Tazi, M. , Majjaoui, S. and Benjaafar, N. (2020) Outcomes of External-Beam Radiation Therapy Boost with Conventional Fractionation in Cervical Cancer: A Retrospective Analysis about 133 Cases. Journal of Cancer Therapy, 11, 547-560. doi: 10.4236/jct.2020.119047.